Try our Advanced Search for more refined results
Life Sciences - February, 2022
297 articles
- Endo, Arnold & Porter Opioid Discovery Called 'Truly Awful'
- Mylan Inks $264M Deal Ending EpiPen Class Price-Hike Suit
- DHS Urges Justices To Pass On $30M Terminated Contract
- The Battle To Confirm Ketanji Brown Jackson
- Moderna Faces Patent Suit Over Its COVID-19 Vaccine
- Smith & Nephew Gets Claims Trimmed In Hip Implant MDL
- GOP Sens. Ask HHS To Nix 'Toxic' Bid To Seize Cancer Drug IP
- Cravath, Goodwin Pilot Viatris' Up To $3.34B Biosimilars Deal
- Opana Buyers Want Pay-For-Delay Trial Split In 3
- Norton Rose Grabs IP Team From Haynes And Boone
- Bankrupt Stem Cell Biz To Pay $3.65M In Class Settlement
- Bankruptcy Is Optimal Venue For Mass Tort Cases
- Winston & Strawn Snags NY Real Estate Partner
- Party Leaders Vow Open Minds For New High Court Pick
- DOJ Has Few Allies, Many Foes In High Court Opioid Brawl
- How Judge Jackson Beat Out Competition For High Court Nod
- Why Ketanji Brown Jackson Honored This Historic Judge
- NJ Judge Scraps Claims In 2 Horizon Drug Patents
- 1st Circ. Judge Selya Says Jackson Will Be 'Balanced'
- Cannabis Bill Roundup: Legalization Bids Advance In SD, Md.
- Zetia Buyers Get Narrow Market In Generic-Delay Suit
- 6th Circ. Won't Revive Ex-P&G Worker's Benefits Suit
- Litigator Makes Move From Bartlit Beck To Winston & Strawn
- Stericycle Takes $81M Hit On Bribery Deal With DOJ, SEC
- Biden's Supreme Court Pick Was Star Debater In Miami
- The Key To Turning Solid Briefs Into Winning Briefs
- What's At Stake In Doctors' Opioid Liability Case In High Court
- Generic-Drug Maker Takes Novartis Battle To Full Fed. Circ.
- ABI Panelists, US Chamber Support Ch. 11 3rd-Party Releases
- J&J, Drug Distributors' $26B Opioid Settlement Is Finalized
- Biohaven Inks Up To $1.24B Deal For Epilepsy Drug Biz
- Jones Day Hires International Arbitration Pro From Dentons
- J&J Talc Unit's Ch. 11 Case Allowed To Go Forward
- 6 Judge Ketanji Brown Jackson Opinions To Read Now
- Biden Nominates Judge Ketanji Brown Jackson To High Court
- DuPont Spinoff Must Face Investors' Enviro Liabilities Suit
- Anthem BCBS Gets Trans Worker's Discrimination Suit Tossed
- FDA Rips CytoDyn's 'Concerning' COVID Video
- FWS Sued For Delayed Review Of Pesticides' Species Impacts
- US Again Places 2nd In Global Patent Protection
- IP Forecast: PayPal Looks To Halt Inventor's Patent Campaign
- Juul Deal Was Not Why Altria Closed Rival, FTC Judge Finds
- Teligent Says Stalled Plan Talks Make Liquidation Best Option
- Steps For Universities As DOJ Shifts Foreign Influence Policy
- FDA Commits To Compounding Drug Rulemaking
- Health Workers Can't Get Freeze On NY Vaccine Mandate
- UnitedHealth Unit Pays $5.8M To End Mass. Drug Price Probe
- Ballard Spahr M&A Leader Sees Bright Future For Deal-Making
- Allen & Overy To Launch In Boston With Ex-Goodwin Attys
- Medtronic Can't Shake Illegal Kickback Suit
- Real Estate Rumors: City National, Bullfinch, Benjamin Group
- Racehorse Trainer Snared In Doping Scandal Gets 3 Years
- Telehealth Fraud Not An Easy FCA Target, DOJ Attys Say
- Trade Org Urges Gov't Action On Hemp-Derived Intoxicants
- What To Know About The Growing PFAS Litigation
- Pfizer Drops Case Alleging Ex-Employee Stole Pharma Data
- USPTO Says Arthrex Patent Do-Over Bid Could Paralyze Gov't
- AstraZeneca Says Patent Office's Fintiv Rule Unlike Any Other
- Shkreli Banned As A Public Co. Leader After Pharma Blacklist
- Philip Morris Attys Nab $575K Fee In Extinguished E-Cig Suit
- Tainted Products Force Hand Sanitizer Maker Into Ch. 11
- Walgreens, Drugmakers Can't Get Stay In Opioid Bellwether
- After West Texas Ruling, Patenting AI Could Be More Nuanced
- Mallinckrodt Wins Approval Of $66M Securities Deal
- Baxter Settles SEC Charges Over Forex Accounting Controls
- Valeant Judge OKs $23M To End 'Secret' Pharmacy RICO Suits
- Cameras, Cancer Drug And Soup Dodge Justices' IP Scrutiny
- Maker Of Recalled COVID-19 Tests Accused Of False Labeling
- FDA Urged To Rethink CBD Status In New Trade Org. Petition
- Advocacy Group Criticizes Pfizer's COVID-19 Pill IP Bids
- Groups Say FERC's Utility Accounting Rules Need Changes
- Importer Nabs Tariff Classification Win For Medical Packaging
- Stryker Must Face FCA Claim In Medical Device Fraud Suit
- Charities Ensnared In NJ Antitrust Suit Over Cancer Drugs
- Orrick Adds Life Sciences Atty From Morgan Lewis
- Kirkland Snags $200K Fees From NY In Opioid Surcharge Suit
- Irish High Court Asks ECJ For Guidance On Drug Patent
- NJ Medical Pot Hopefuls Say Agency Snubbed Court Ruling
- Cannabis Bill Roundup: Legalization Bids In The Heartland
- J&J Talc Unit Says Ch. 11 Only Recovery Option For Claimants
- Grassley Squeezes Feds For Info On STEM Work Program
- Perrigo Investors' Attys Score $11.5M From Tax Bill Settlement
- Prenatal Defect Test Maker Hit With Suit Over False Positives
- Buyers Hit Abbott Labs With Baby Food Suit Amid FDA Probe
- Walter Dellinger's Little-Known, Outsize Impact On Legal Aid
- Blood Plasma Cos. Can't Revive Visa Suit, D.C. Circuit Told
- Health Hires: Horizon Therapeutics, Zynerba
- Trainer In Horse Doping Scheme Deserves 3 Years, Feds Say
- Sacklers Offer Another $1.6B For Purdue Ch. 11 Settlement
- Celanese Pays $11B For DuPont Unit In Deal Led By 3 Firms
- Talc Claimants Say J&J Unit's Ch. 11 Benefits Parent Co. Only
- IP Forecast: Activision Blizzard Set For Trial Over Data Patent
- CBD Co. Mostly Escapes Claims By Ex-Stratton Oakmont Rep
- J&J Units Aim To Hit Brakes On Generic Schizophrenia Drug
- Attys From Four Firms Named To Co-Lead Philips CPAP MDL
- How Fintiv Stipulations Affect IPR Institution, By The Numbers
- Moderna's South African Patent Filings Raise Activists' Alarms
- Nurse, Marine Reservist Charged With Selling Fake Vax Cards
- Why I'll Miss Arguing Before Justice Breyer
- Amid Historic Spending, Congress Should Strengthen FCA
- Judge Axes HHS Letter Over AstraZeneca Discount Dodging
- Australian Condom Co. Takes 'Naked' TM Fight To Court
- Perkins Coie Hires Ex-Jones Day Patent Atty & Inventor
- 5th Circ. Backs Workers Fighting United Airlines Vax Mandate
- NY Cannabis Regulators Approve New Medical Pot Rules
- Life Sciences Group Of The Year: Williams & Connolly
- Purdue Gets OK For 2-Week Opioid Suit Freeze Extension
- Invisalign Must Face Fed Antitrust Claims, Some State Claims
- Endo Urges Opioid Judge's DQ For 'Egregious' Ethics Lapses
- Pfizer Prevails In Proposed Class Action Over Chantix Recall
- '150 Billion Pills' Gaffe Imperils NY AG's Opioid Win Over Teva
- Tesla, Comcast, Dell, Mylan Join Tech Cos. In Fighting Fintiv
- Westco Says Workers Not Harmed By 'Secret' Pension Plan
- Texas Sues Biden Over Air Travel Mask Mandate
- Boston Firefighters Say 3M, DuPont Hid PFAS Cancer Risk
- Ex-Pharma CEO Wants Landmark Opioid Conviction Tossed
- Calif. Gets Pay-For-Delay Ban Partially Revived
- Air Force Can't Make Unvaccinated Ga. Officer Retire
- What Cos. Can Learn From The 2021 FCA Recovery Statistics
- More Antitrust Scrutiny Of Pharma Won't Help Patient Health
- Austrian Pharma Co.'s €142M Award Nixed In Germany
- Cities, Tribes, Schools Fight Toss Of McKinsey Opioid MDL
- Monsanto, BASF Say $75M Dicamba Verdict Misplaced Blame
- DOJ Pans Glenmark 'Fishing Expedition' For Grand Jury Docs
- Recent Rulings Show Lawyer Criticism Of Judges Is Perilous
- Haynes And Boone Nabs Oblon McClelland Vet In DC
- Ch. 11 For J&J Talc Unit Only Wise Choice, Top Lawyer Says
- Med Co. Trims But Can't Ax Spinal Implant Patent Suit
- Fed. Circ. Forum Selection Ruling Serves As 'Cautionary Tale'
- Alexion, Chugai Settle Blood Drug IP Row On Day Of Trial
- Defiant Priest May Face Ban After Verdict In SEC Fraud Case
- Takeaways From DOJ Fraud Section's 2021 Year In Review
- Fed. Circ. Says 'Ad Hoc' Group Can't Revive Amarin Drug IP
- Genesis Unicorn SPAC Leads 2 IPOs That Raise $135M Total
- CVS Wants Consolidated Drug Pricing Suit In Arbitration
- Medline Seeks End To Hartford's Libel Suit Coverage Fight
- Life Sciences Group Of The Year: Paul Weiss
- Breyer's Role In Courthouse Design Sets A Judicial Template
- Shearman & Sterling Adds Arbitration Pro From Jones Day
- In Close Vote, Senate Confirms Califf To Head FDA
- Endo Opioid Saga 'Like A John Grisham Movie,' Judge Says
- Talc Claimants Argue Bad Faith In J&J Unit's Ch. 11 Trial
- Lab Owners Must Face $24M Medicaid Overpayment Claims
- Contractor, Investors Reach $3.3M Deal In COVID Tests Suit
- Okla. Rolled Out Medical Pot Too Quickly, Watchdog Finds
- Ark. Pot Cos. Say State's New Rules Are Unconstitutional
- Mallinckrodt Seeks Last Extension Of Ch. 11 Acthar Suit Pause
- Expect Aggressive Life Sciences Enforcement In 2022
- All But 2 Claims Trimmed In Pa. Pelvic Mesh Case
- Pfizer Hits Teva With Suit Over Arthritis Drug Patent
- Bioness Stockholders Challenge $110M Sale To Bioventus
- California Biotech Co. Appoints 1st General Counsel
- Pa. AG Says Philadelphia Vaccine Nonprofit Must Dissolve
- Life Sciences Group Of The Year: Gibson Dunn
- 5 Key Details As Endo Is Rocked Again By Opioid Default
- FDA Won't OK Pfizer's Under 5 Vax Until 3-Shot Study Is Done
- Taiwanese Pharma Co. Says €142M Award Can't Be Enforced
- Fed. Circ. Upholds J&J's Win In Surgical Tool IP Fight
- Cannabis Bill Roundup: A Cure For Hemp's THC Headaches?
- Fed. Circ. Doubts 'Ad Hoc' Group Can Revive Amarin Drug IP
- Sharply Split Full Fed. Circ. Won't Eye Skinny Label Ruling
- FTC No Longer Pressing For Caris Docs In Illumina Case
- Health Hires: Reed Smith, McGuireWoods
- Sober Home's Medical Chief Convicted Of $110M Billing Fraud
- Law Professors Say J&J Talc Ch. 11 Is Shielding Assets
- Shackelford Scoops Up More Winstead Attys In Texas
- Taxation With Representation: Kirkland, Dechert, Gibson Dunn
- Life Sciences Group Of The Year: Covington
- Endo Hit With New Default Ruling In Opioid Discovery Debacle
- Walgreens OK'd To Pursue Crowell & Moring Breach Claims
- Wash. Lays Out $38B Opioid Abatement Plan To Trial Judge
- Astellas Workers Win Class Cert. In Suit Over 401(k) Losses
- J&J Unit Says Ch. 11 Is Best Response To Talc Suit 'Tsunami'
- IP Forecast: 9th Circ. To Hear Copyright Row With Shyamalan
- Fla. Clinics Can't Ditch Gilead's HIV Drug Charity Scam Claims
- 5th Circ. Grants New Trial Over Sanofi Chemo Drug
- NJ Town Violated Civil Rights In Blocking Development
- J&J Can't Be Allowed To Dodge Civil Justice With Bankruptcy
- Fed. Circ. Axes Inventor's $1.25M IP Win Under On-Sale Bar
- Life Sciences SPAC Pulls Plans For $200M IPO
- Split Fed. Circ. Won't Restore 4 Narcan Patents
- 3M Wants High Court Look At Surgical Blanket Expert Ruling
- Clifford Chance, Kirkland Rep £1.9B PE Deal For Informa Unit
- Boston Hospitals Say Vax Rule Must Survive 1st Circ. Review
- Drugmaker Loses Suit Over Clinical Trial For Heart Medicine
- Split 5th Circ. Won't Stay Block Of Fed. Worker Vax Mandate
- Texas Wants National Guard Vaccine Mandate Halted
- Racehorse Trainers, Vet Can't Dump Doping Scheme Charges
- Zetia Buyers Defend Class Cert. As 'Common Business Sense'
- Suit Says Aetna's Fertility Treatment Policy Is Discriminatory
- NY Judge OKs Canadian Entities' Late Purdue Ch. 11 Appeal
- Medtronic Can't Ditch All Claims In Faulty Pacemaker Suit
- BigLaw Must Nix All-Or-Nothing Work Model To Retain Talent
- Cooperator In Meningitis Outbreak Case Gets Time Served
- New FCA Stats Fuel Debate Over Health Enforcement Fixation
- Feds Fight Alford Plea For Ex-Prof Accused Of Insider Trading
- Maine's Pot Residency Rule Unconstitutional, 1st Circ. Told
- Opioid Crisis In Wash. State 'Unique,' Judge Told
- Del. Judge Bars Trustee Toss Of Fecal Test Firm's Ch. 7 Docs
- Lost Theranos Data 'Paints Picture Of Deception,' Judge Says
- Senators Hear Possible Solutions To 'Texas Two-Step' Issues
- FSD Pharma Says Delaware Suit Belongs In Ontario
- FTC Gets More Time To Review Pfizer's $6.7B Arena Deal
- Fed. Circ. Says Forum Selection Clauses Can Bar PTAB Fights
- Sun Pharma, Lupin Agree To Drop Eye Pain Patent Dispute
- Canadian Entities Seek Late Appeal In Purdue Ch. 11 Case
- Biogen Hid Issues With Alzheimer's Drug, Investor Suit Claims
- Key Players In Boy Scouts Ch. 11 Attack Nondebtor Releases
- Important Product Liability Practice Trends To Watch In 2022
- Biden's Supreme Court Nominee Should Have 5 Key Qualities
- Rosen Law Firm Nabs Lead In Biotech Investor's Drug Row
- Teligent Lender Slams Creditor Group Bid To Claw Back Cash
- 1st Circ. Spots 'Gap' In Cancer-Drug Suit Against Karyopharm
- Ex-Spine Doc Owes $13M To Women Over Faulty Surgeries
- Align, 3Shape Ink IP, Antitrust Deal Over Clear Braces
- Calif. Lawmakers OK More Paid COVID Leave For Workers
- J&J Drops Bid To Block Reuters Story As Attys Trade Barbs
- Service Members Defend Challenge To Vax Approval, Mandate
- Generics Co. Accuses Ex-Exec Of Swiping Trade Secrets
- PhRMA Backs AstraZeneca In Bid For Fed. Circ. Redo
- FDA Probing Possible Death Risk Of Lymphoma Drug
- Investors Late Over AbbVie's Failed Shire Deal, Court Says
- SEC Is Pushing Boundaries In Insider Trading Enforcement
- Texas Strikes $225M Deal With Teva Over Opioid Crisis
- AstraZeneca, Merck Want Calquence Generics Halted
- Law360 Seeks Members For Its 2022 Editorial Boards
- Using 3rd-Party Releases In Chapter 11 After Court Pushback
- Flint Residents' Attys Awarded $39.6M As Part Of Water Deal
- Ex-Theranos Exec Seeks To Block Holmes Trial Evidence
- Reuters Says J&J Too Late To Nix Story Over Atty Leak Claim
- Belcher Must Cover Hospira's Legal Fees In Patent Fight
- After Patent Drama, FDA OKs Generic Restasis
- Anesthesiology Group Puts To Rest Drugmaker's Libel Suit
- UnitedHealth Units Beat ERISA Drug Overcharge Claim
- PTAB Judge Grills UC On Evidence It Invented CRISPR First
- Shkreli's Lifetime Pharma Ban Upheld
- Cadwalader's Corporate Group Nabs Investment Firm Ex-GC
- China's Expanded Data Clampdown Rankles US Lawyers
- EU Suspends Deadline For Illumina's $8B Grail Deal
- Wilson Sonsini-Led Biotech Firm Rallies After $124M IPO
- Final Approval In Glumetza Antitrust Deal Gives Attys $50M
- 2 Recent Decisions Highlight Ambiguity As FCA Defense
- Ex-NECC Execs Seek New Trial After Revived Convictions
- Feds Say J&J Talc Trust Can't Exclude Medicare Claims
- Purdue Asks For New Extension On Opioid Suit Freeze
- Pharma Co. Can't Escape Most Of Fluoride False Ad Suit
- Philly, Pittsburgh DAs Lose Bid To Stop Opioid Settlement
- Mallinckrodt Ch. 11 Plan Gets Green Light From Del. Court
- J&J Says Talc Plaintiff Attys Fed Confidential Docs To Reuters
- Opioid Trial In Wash. State Briefly Interrupted For Evacuation
- Calif. Judge Unpersuaded To Nix Drugmakers' Opioid Trial Win
- Ex-UChicago Prof Seeks Alford Plea Over Insider Trades
- IP Forecast: 11th Circ. To Eye Biz's $20M Trade Secrets Loss
- Pharma Group Wants EU On Watchlist For Weakening IP
- Scholar Briefs OK'd In J&J Talc Unit's Ch. 11 Dismissal Bid
- Fed. Circ. Affirms Preliminary Injunction In Eye Device IP Row
- Upcoming Rulings Key To Defining PREP Act Protections
- CMA Issues £35M In Fines For Alleged Drug Supply Pact
- Lifetime Ban For Shkreli Means Lifetime Ban, FTC Says
- Asbestos Suit Returns To NJ State Court After Boeing's Exit
- Deals Rumor Mill: Novartis, Cedar Fair, IVI-RMA
- Key Trade Secret Developments Of 2021: Part 2
- Ex-Novartis Exec Didn't Back Retaliation Suit, NJ Court Told
- Mississippi Legalizes Medical Pot After Governor's Signature
- BCBS Unit's $28M Shkreli Deal Poised For Initial OK
- Drug Distributor Stymied On FDA Topics In Wash. Trial Cross
- Hawaiian Airlines Workers Can't Block Vaccine Mandate
- Ex-Execs Say Ch. 7 Trustee Can't Drop Amazon Doc Storage
- Tillis Asks FDA, USPTO To Vet Reports By Drug Patent Critics
- Indivior Again Loses Bid To DQ Bankrupt Suboxone Plaintiff
- Glenmark Wants Grand Jury Evidence In Price-Fixing Case
- Product Trainer Wants Out Of $40M Pot Farm Fire Suit
- Chancery Taps 4 Firms To Lead Emergent Investor Suits
- JPML Sends False Ad Suits Over Sleep Device Cleaners To Pa.
- China Patent Ruling Highlights Anti-Monopoly Law's Reach
- Biden Nominates Michigan District Judge To 6th Circ.
- Ex-Drug Co-Op CEO Convicted In Landmark Opioid Case
- Pfizer Says Ex-Execs Swiped Data For Rival Drug Startups
- The Flaws In The Traditional Approach To Hiring A Law Firm
- Taxotere Eye Damage Suits Consolidated In Louisiana MDL
- Steptoe Adds White Collar Expert To San Francisco Office
- Gerber Accused Of Cutting Anti-Competitive Deal With Perrigo
- Gilead Pays ViiV $1.25B Plus Royalties To End HIV Patent Suit
- Novartis Ducks Regeneron's Antitrust Countersuit To IP Fight
- How Rx Drugs Become Illegal Street Sales Murky, Judge Told
- At Fed. Circ., Novartis Rips Amgen's 'Patent Estate'
- Shkreli Fights Scope Of Pharma Industry Ban
- Law Firms Weathered Frosty January As IPO Activity Slowed
- DOJ Recovers $5.6B In 2021 For 2nd-Highest FCA Haul
- Pfizer Wants FDA's Approval Of COVID Vax For Kids Under 5
- CBD Co. Inks $712K Deal To End Investors' Securities Suit
- ThermoLife Told To Take Injunction Stay Bid Up With Albright
- Roche Unit's Cancer Treatments Draw UPenn Patent Suit
- Purdue Closing In On New Ch. 11 Deal With Sackler Family
- What Pa. Procedure Rule Change Means For 'Snap Removals'
- Ex-Univar Executive Loses Push For Severance Pay
- Tribes Reach $590M Opioids Deal With J&J, Distributors